Derik De Bruin
Stock Analyst at B of A Securities
(3.73)
# 765
Out of 5,138 analysts
222
Total ratings
67.79%
Success rate
16.81%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Buy | $43 → $60 | $48.39 | +23.99% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $139.64 | +18.16% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,460.63 | -4.84% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $235.99 | -6.78% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $41.01 | -34.16% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $112.50 | -2.22% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $20.52 | -36.65% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $47.57 | +6.12% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $387.37 | -3.19% | 14 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $5.92 | +85.81% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $102.43 | -36.54% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $12.79 | +25.10% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $618.72 | +6.67% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $237.68 | -1.13% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $219.70 | -4.42% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $259.79 | +36.65% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $19.75 | +31.65% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $270.87 | +0.05% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $189.49 | -3.95% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $16.50 | +27.27% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $16.79 | +90.59% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $141.65 | -29.40% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $74.98 | +14.70% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.61 | +260.11% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.89 | +243.92% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $182.61 | +42.38% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $9.55 | +1,156.54% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $124.65 | -3.73% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.76 | +226.09% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $715.37 | -67.15% | 3 | Nov 2, 2018 |
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $48.39
Upside: +23.99%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $139.64
Upside: +18.16%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,460.63
Upside: -4.84%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $235.99
Upside: -6.78%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $41.01
Upside: -34.16%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $112.50
Upside: -2.22%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $20.52
Upside: -36.65%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $47.57
Upside: +6.12%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $387.37
Upside: -3.19%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $5.92
Upside: +85.81%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $102.43
Upside: -36.54%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $12.79
Upside: +25.10%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $618.72
Upside: +6.67%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $237.68
Upside: -1.13%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $219.70
Upside: -4.42%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $259.79
Upside: +36.65%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $19.75
Upside: +31.65%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $270.87
Upside: +0.05%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $189.49
Upside: -3.95%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $16.50
Upside: +27.27%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $16.79
Upside: +90.59%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $141.65
Upside: -29.40%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $74.98
Upside: +14.70%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.61
Upside: +260.11%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.89
Upside: +243.92%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $182.61
Upside: +42.38%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $9.55
Upside: +1,156.54%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $124.65
Upside: -3.73%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.76
Upside: +226.09%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $715.37
Upside: -67.15%